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A B S T R A C T
The CD8 T cell response to the HLA-A2-restricted epitope LLWNGPMAV (LLW) of the non-structural protein 4b
of Yellow Fever Virus (YFV) is remarkably immunodominant, highly prevalent and powerful in YFV-vaccinated
humans. Here we used a combinatorial peptide library screening in the context of an A2/LLW-specific CD8 T cell
clone to identify a superagonist that features a methionine to isoleucine substitution at position 7. Based on in
silico modeling, the functional enhancement of this LLW-7I mutation was associated with alterations in the
structural dynamics of the peptide in the major histocompatibility complex (pMHC) binding with the T cell
receptor (TCR). While the TCR off-rate of LLW-7I pMHC is comparable to the wild type peptide, the rigidity of
the 7I peptide seems to confer less entropy loss upon TCR binding. This LLW-7I superagonist is an example of
improved functionality in human CD8 T cells associated with optimized ligand rigidity for TCR binding and not
with changes in TCR:pMHC off-rate kinetics.
1. Introduction
T cells respond to proteic antigens in the form of short peptides,
usually between 8 and about 20 amino acids in length. Cytotoxic CD8 T
cells recognize peptides derived from proteins processed by the en-
dogenous pathway and presented on Major Histocompatiblity Complex
(MHC) Class I molecules for interaction with cognate T cell receptors
(TCRs). Upon encounter with their cognate peptide-MHC (pMHC)
complex, TCR triggering activates a signaling cascade leading to the
proliferation and initiation of effector functions by T cells.
Several studies suggest that a potent T cell response is related to a
lower dissociation constant (KD) and/or a longer monomeric dissocia-
tion constant rate (koff) (Gannon et al., 2015; Hebeisen et al., 2015;
Holler et al., 2001; La Gruta et al., 2006; Matsui et al., 1994; Tian et al.,
2007). A recent report on self/tumor and virus-specific CD8 T cell
clones showed that koff values offer a better prediction of the CD8 T cell
potency (Allard et al., 2017). However, TCRs often weakly interact with
pMHC complexes (1−100 μM) and with fast dissociation kinetics
(koff>0.01) (Cole et al., 2007; Davis et al., 1998; Stone and Kranz,
2013). As low affinity T cells participate in the anti-tumor immune
response, the TCR-pMHC binding parameters are of particular im-
portance in the context of immunotherapies of cancer. Several clinical
trials conducted on cancer patients examined the impact of adoptively
transferred T cells expressing affinity-improved TCRs on clinical out-
come. They concluded that optimal T cell function occurs at inter-
mediate TCR:pMHC binding strength, highlighting a TCR affinity
threshold for maximal T cell responses (Dutoit et al., 2001; Gannon
et al., 2015; Speiser et al., 2008; Tan et al., 2015; Zhong et al., 2013).
In the present study, we explore the functionality of a TCR identified
in a CD8 T cell clone (YF5048) isolated from a healthy volunteer vac-
cinated with the live-attenuated Yellow Fever virus vaccine YF-17D.
YF5048 is specific for the immunodominant HLA-A*0201-restricted
epitope LLWNGPMAV (NS4b 214–222; hereafter A2/LLW). Upon vac-
cination with YF-17D, the CD8 T cell response to this A2/LLW epitope
in vivo is remarkably immunodominant: it is highly prevalent (the
majority of HLA-A*02 individuals will raise a response) and pre-
dominates the specificity of the response; this epitope alone can re-
present in the range of 10 % of the CD8 T cell response (Akondy et al.,
2009; Blom et al., 2013; Bovay et al., 2017; Marraco et al., 2015; de
Melo et al., 2013). Previously, we reported the crystal structure of the
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LLW peptide in complex with HLA-A*02 and performed in silico mod-
eling of TCR binding based on the TCR sequence of clone YF5048
(Bovay et al., 2017). Here we describe an altered peptide of the LLW
nonamer that induces increased functionality in the YF5048 clone and
investigate the particular structural and dynamic properties that are
associated with such increased antigen sensitivity.
2. Material and methods
2.1. Sizing scan
The following mixtures were used to define the peptide length
preference of individual TCRs: X8, X9, X10, X11, X12, and X13 (where X is
any of the 19 L-amino acids excluding cysteine; Pepscan Presto)
(Ekeruche-Makinde et al., 2013). The YF5048 clones were washed and
rested overnight in R5 medium (RPMI 1640 supplemented with 100
units/mL penicillin, 100 μg/mL streptomycin, 2 mM l-glutamine, and
5% heat-inactivated fetal calf serum (all Invitrogen)). In U-bottom 96-
well plates, 6 × 104 target cells were incubated with sizing scan mix-
tures at 1 mM in duplicate for 2 h at 37 °C. After peptide pulsing, 3 ×
104 YF5048 clone were added and the assay was incubated overnight at
37 °C. Subsequently, the supernatant was harvested and assayed for
MIP-1β by ELISA according to the manufacturer's instructions (R&D
Systems).
2.2. 51Chromium release assay
The 51Chromium release assay was performed as described pre-
viously (Bovay et al., 2017). The HLA-A*02+ human mutant cell line
CEMx721.T2 (American Type Culture Collection) was used as target by
labeling with 51Cr for 1 h at 37 °C, followed by extensive washing.
Target cell killing was assessed by chromium release in the supernatant
upon co-culture with the YF5048 clone (effector cells) at the Effector:
Target ratio of 10:1 for 4 h at 37 °C in V-bottom microwells, in the
presence of serial dilutions of the peptides, measured using a gamma
counter and calculated as:
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−
−
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2.3. Intracellular cytokine staining assay
The staining was performed as described previously (Bovay et al.,
2017). The YF5048 clone was stimulated with peptide-loaded T2 cells
at the E:T cell ratio of 1:2 for 4 h at 37 °C in the presence of Brefeldin-A
(Sigma-Aldrich) and anti-CD107a-PE antibody (BD Biosciences). Then,
cells were stained with anti–CD8–APC-AF750 antibody (Beckman
Coulter) at 4 °C for 30 min. After washing in PBS, cells were incubated
with eFluor 455UV Fixable Viablity Dye (eBioscience) at 4 °C for 30
min, and fixed with 0.36 % formaldehyde at 4 °C overnight. Cells were
washed and stained intracellularly with anti-IFNγ-PC7, anti-TNFα-
A700, GranzymeB-APC (BD Biosciences) and anti-IL-2-FITC antibodies
(BD Biosciences) in phosphate-buffered saline (PBS) with 5 mM EDTA,
0.2 % bovine serum albumin (FACS buffer) with 0.1 % saponin for 30
min at 4 °C. Samples were acquired using an LSRII-SORP flow cyt-
ometer (BD Biosciences, five-laser configuration). The data were pro-
cessed with FlowJo (Tree Star Inc., v9.5.2).
2.4. pMHC multimer staining
The T cell clone was incubated with various concentrations of the
PE-labeled multimers (TC Metrix Sàrl) for 30 min in FACS buffer with
20 mM NaN3 at 4 °C. Samples were acquired using a SORP-LSR II flow
cytometer (BD Biosciences). The data were processed with FlowJo
(v.9.7.6; Tree Star) and geometric mean fluorescence intensity values
were plotted and analyzed using GraphPad Prism software (V6;
GraphPad). Dissociation constants KD were calculated assuming a one-
site binding model as implemented in GraphPad.
2.5. NTAmer staining and dissociation kinetic measurements
Dually labeled pMHC multimers built on NTA-Ni2+-His-tag inter-
actions called NTAmers (synthetized by TCMetrix Sàrl) were used for
dissociation kinetic measurements (Schmidt et al., 2011, 2013). Stain-
ings with dually PE- and Cy5-labeled A2/LLW-specific NTAmers and
data analysis were done as previously described (Hebeisen et al., 2015;
Schmidt et al., 2011). Briefly, staining was measured at 4 °C using a
thermostat device on a SORP-LSR II flow cytometer (BD Biosciences).
Following 30 s of baseline acquisition, imidazole (100 mM) was added.
PE and Cy5 fluorescence were measured during the following 5 min.
Data were processed using the kinetic module of the FlowJo software
(v.9.7.6; Tree Star), and corrected mean fluorescence intensity values
were plotted and analyzed using GraphPad Prism. An irrelevant clone
(recognizing the HLA-A*0201-restricted CMV epitope pp65495−504:
NLVPMVATV) was used to reference the non-specific background
staining. In order to overcome the potential differences of NTAmer
molecule’s quality, the Cy5 decay values of the NTAmers specific for the
mutant peptides were normalized to the PE decay value of the WT
NTAmer.
− =Half life kln2/ off
2.6. Protein expression, refolding and purification
HLA A*0201 α-chain and β2 m were expressed separately, without
post-translational modification, as insoluble inclusion bodies (IBs) in
competent Rosetta (DE3) Escherichia coli cells, using 0.5 M IPTG to
induce expression as described (MacLachlan et al., 2017). Briefly, for a
1 l pMHC refold, 30 mg HLA-A*0201 α-chain was mixed with 30 mg β2
m and 4 mg peptide at 37 °C for 15 min with 10 mM DTT. This mixture
was added to cold refolding buffer (50 mM Tris, pH8, 2 mM EDTA, 400
mM L-arginine, 6 mM cysteamine hydrochloride, and 4 mM cystamine).
Refolded complexes were mixed at 4 °C for> 6 h. Dialysis was per-
formed against 10 mM Tris, pH8.1, until the conductivity of the refolds
was less than 2 mS/cm. Refolded proteins were filtered and purified by
ion exchange using a Poros50HQTM column (GE Healthcare, Buck-
inghamshire, U.K.) followed by gel filtration directly into crystallization
buffer (10 mM Tris pH8.1, 10 mM NaCl) or PBS (137 mM NaCl, 3 mM
KCl, 8 mM Na2HPO4, 1 mM KH2PO4) using a Superdex 200 HRTM
column (GE Healthcare, Buckinghamshire, U.K.). Protein quality was
analyzed by Coomassie-stained SDS-PAGE under non-reducing or re-
ducing conditions.
2.7. Thermal stability of HLA-A*0201-peptide complexes
Thermal stability of A2/peptide complexes was assessed by circular
dichroism (CD) spectroscopy as described in detail in Fuller et al., 2017
(Fuller et al., 2017). Briefly, after purification by gel filtration chro-
matography in PBS, proteins were diluted to ca. 3.5 μM, and melting
curves were recorded at 218 nm in 0.1-cm cells using an Aviv 215
spectrometer (Aviv Biomedical Inc., Lakewood, NJ). Denaturation was
monitored from 4 °C up to a temperature when protein precipitation
occurred using parameters resulting in a heating rate of ∼36 °C/h.
Melting curves were analyzed assuming a two-state native (N) to de-
natured (D) transition N3 ↔ 3D with the melting temperature Tm and
van't Hoff's enthalpy ΔHvH at the midpoint of the transition as fitting
parameters.
2.8. Crystallization, diffraction data collection, and model refinement
All protein crystals were grown at 18 °C by vapor diffusion via the
“sitting drop” technique. 200 nl of each pMHC (20 mg/mL) in
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crystallization buffer was added to 200 nl of reservoir solution. A2/
LLW-4A crystals were grown in 0.1 M sodium cacodylate pH 6.0, 0.2 M
ammonium sulphate, 25 % PEG 4000. A2/LLW-7I crystals were grown
in 0.1 M Mes pH 7.0, 0.2 M ammonium sulphate, 25 % PEG 8000. A2/
LLW-8H and A2/LLW-8Q crystals were grown in 0.1 M sodium caco-
dylate pH 6.5, 0.2 M ammonium sulphate, 20 % PEG 4000. All crystals
were soaked in 30 % ethylene glycol before cryo-cooling. All crystal-
lization screens and optimization experiments were completed using an
Art-Robbins Gryphon dispensing robot (Alpha Biotech Ltd., UK). Data
were collected at 100 K at the Diamond Light Source (Oxfordshire, UK)
as described previously (Motozono et al., 2015). All data sets were
collected at a wavelength of 0.98 Å using an ADSC Q315 CCD detector.
Reflection intensities were estimated with the XIA2 package, and the
data were scaled, reduced, and analyzed with the SCALA and CCP4
package. Structures were solved with molecular replacement using
PHASER. A solution could be obtained with a search model taken from
Protein Data Bank entry. Sequences were adjusted with COOT, and the
models were refined with REFMAC5. Graphical representations were
prepared with PyMOL. The reflection data and final model coordinates
were deposited in the Protein Data Bank: A2/LLW-4A (6SS7), A2/LLW-
7I (6SS8), A2/LLW-8H (6SS9), A2/LLW-8Q (6SSA).
2.9. Modeling the TCR-pMHC complexes
As described previously (Bovay et al., 2017), the 3D structure of the
TRAV12−2/TRBV9 TCR in complex with HLA-A2 and the LLW peptide
was modeled from three experimental structures: 3HG1 (Cole et al.,
2009) and 4QOK (Madura et al., 2015), containing a complex between
the TRAV12−2/TRBC1 TCR in complex with HLA-A2 and the ELAGI-
GILTV or EAAGIGILTV peptides, respectively, and the experimental
structure obtained in this study for the complex between HLA-A2 and
the LLWNGPMHV, LLWNGPMQV, and LLWAGPMAV peptides. The se-
quence alignment between TRBV9 and TRBC1 was performed using the
MUSCLE program (Edgar, 2004). The sequence identity between the
variable part of the TRBV9 and TRBC1 TCR beta chains is 30 %. Based
on this sequence alignment, the model was obtained using the Modeller
program (Eswar et al., 2001; Šali and Blundell, 1993). 1000 models
were generated by satisfaction of spatial restraints through minimiza-
tion and simulated annealing, and the model with the best Modeller
objective function was retained. Molecules were visualized and ana-
lyzed using UCSF Chimera (Pettersen et al., 2004).
2.10. Molecular dynamics simulations
MD simulations were performed with GROMACS (Abraham et al.,
2015; Bjelkmar, 2010) version 2018.3 in periodic boundary conditions,
using the all-atom CHARMM27 force field (MacKerell et al., 1998) and
the TIP3P water model. The number of Na+ and Cl− ions in solution
was adjusted to neutralize the system and reach the physiological
concentrations of 0.154 M. Before starting the MD simulations, missing
residues and loops were modelled using the Dunbrack rotamer libraries
(Dunbrack, 2002) and the Modeller program (Eswar et al., 2001). Ti-
tratable side chains were protonated so as to allow hydrogen bonds
with neighbouring residues. Electrostatic interactions were calculated
with the Ewald particle-mesh method (Essmann et al., 1995) with a grid
spacing of 1.2 Å. A cut-off of 12 Å was applied for the real-space
Coulomb and van der Waals interactions. Bonds involving hydrogen
atoms were constrained using the P-LINCS algorithm (Hess et al.,
2008). The system was coupled to a Parinello-Rahman barostat with a
relaxation time of 1 ps. The solute and the solvent were separately
coupled to two nose-hoover thermostats (Bussi et al., 2007), each with a
relaxation time of 0.2 ps. A time integration step of 2 fs was used, with a
temperature of 300 K and a pressure to 1 bar during the production
trajectory. Initial Cartesian coordinates were taken from the experi-
mental X-ray structures of pMHC molecules obtained in this study.
Peptide mutations, M7I, A8H and A8Q were introduced using the
swapaa command of UCSF Chimera (Pettersen et al., 2004) v 1.12 and
the Dunbrack backbone-dependent rotamer library (Dunbrack, 2002).
Initial structures were energy optimized, heated from 0 to 300 K in 0.4
ns, equilibrated for a further 1 ns restraining each solute non-hydrogen
atom to its original position, and finally equilibrated for 2 ns without
restraints before data collection. 3 MD simulations were carried out for
the WT and mutated peptides to assess the reproducibility of the results.
Each MD simulation had a production time of 140 ns, saving co-
ordinates every 0.05 ns.
2.11. Statistical analysis
P-values from unpaired t-tests and data visualizations were obtained
using the software Microsoft Excel 14.2.0 and GraphPad Prism 8.1.0. A
p-value ≤ 0.05 was considered statistically significant.
3. Results
3.1. Identification of superagonist peptides for the A2/LLW-specific CD8 T
cell clone YF5048
First, we assessed the peptide length preference of the YF5048 clone
by the functional recognition of a custom-built “sizing scan” comprising
random peptide libraries of different lengths (8 to 13-mer) (Ekeruche-
Makinde et al., 2013). Previous data suggest that CD8 T cell clones
exhibit preference for the length of the index peptide (Ekeruche-
Makinde et al., 2013): as expected, we validated that the YF5048 clone
exhibited a preference for the length of the index peptide (9-mer)
(Fig. 1A).
In order to identify potential superagonist peptides for the YF5048
clone, we performed a combinatorial peptide library (CPL) screening
(Bovay et al., 2017; Galloway et al., 2019). Only few non-index residues
at positions 7 and 8 could increase the response compared to the index
peptide (Bovay et al., 2017). In particular, the CPL results suggested
that LLW-7I (LLWNGPIAV), LLW-8H (LLWNGPMHV) and LLW-8Q
Fig. 1. Peptide recognition signature of an individual TCR derived from clone YF5048. A, Peptide length preference was determined by sizing scan comprising
random peptide mixtures of different lengths. Values are expressed as the concentration of MIP-1β secreted in the supernatant measured by ELISA in duplicate (mean
and SD). B, Recognition of 3 individual peptides chosen from the CPL assessed by MIP-1β activation in duplicate with graded concentrations of the peptides (mean
and SD).
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(LLWNGPMQV) are optimal peptides (Bovay et al., 2017).
Next, we tested the peptide sequences revealed by the nonamer CPL
screening by stimulating with peptides individually (Fig. 1B). Indeed,
the ELISA confirmed that all three mutant peptides (LLW-7I, -8H and
-8Q) induced the expression of the cytokine MIP-1β at superior levels
than stimulation with LLW-WT. The LLW-4A (LLWAGPMAV) peptide
served as a negative control. As shown previously (Bovay et al., 2017),
residue Asn4 of the peptide made numerous favorable interactions with
the TCR, including hydrogen bonds with Ser32 and Asp92 of TCRα (Fig
S1). The lack of immune response to A2/LLW-4A is therefore in line
with the loss of critical TCR/pMHC interactions. As previously reported,
LLW-4R (LLWRGPMAV) failed to activate the TCR (Bovay et al., 2017).
We further investigated the antigen sensitivity to the mutant pep-
tides revealed by the CPL screening. First, we assessed the killing ca-
pacity of the YF5048 clone using a chromium release assay after sti-
mulation with these peptides (Fig. 2A and B). Upon titration, the LLW-
7I peptide led to an approximately 10-fold higher antigen sensitivity
than LLW-WT (Fig. 2A). This decreased EC50 was significant (Fig. 2B).
The response to the LLW-8H and -8Q peptides were comparable to the
LLW-WT.
Second, we compared the degranulation and secretion of cytokines
upon stimulation with the various peptides by flow cytometry.
Stimulation with titrating amounts of the LLW-7I peptide led to an
approximate 10-fold increased secretion of all measured cytokines
compared to LLW-WT titration (Fig. 2C and Fig S2). The calculated
EC50 of the LLW-7I peptide titration was approximately 10-fold better
than LLW-WT for IFNγ, TNFα and IL-2 (Fig. 2D). Similar effects were
observed for the degranulation marker CD107a (Fig. 2C and D). The
peptides LLW-8H and LLW-8Q did not improve significantly the antigen
sensitivity compared to LLW-WT. Also, the LLW-7I peptide induced a
higher polyfunctionality at low peptide concentrations compared to the
LLW-WT peptide (Fig S3).
3.2. The 7I mutation in LLW improves the TCR:pMHC dissociation constant
KD without impacting the monomeric off-rate
We hypothesized that the enhanced antigen sensitivity of the LLW-
7I mutant could be a consequence of a stronger TCR:pMHC interaction.
In order to characterize the interaction between the TCR and the ago-
nist pMHC complexes, we first used fluorescently-labeled pMHC mul-
timers at graduating concentrations and measured the fluorescence
intensity upon staining of the YF5048 clone in order to calculate the
dissociation constant KD value (kon/koff) (Fig. 3A and B) (Wooldridge
et al., 2009, 2012). The A2/LLW-7I, -8H and -8Q multimers stained the
YF5048 clone with a slightly stronger intensity compared to the A2/
LLW-WT multimer (Fig. 3A) and bound the TCR with a lower KD
(Fig. 3B).
Previous reports have linked higher functional avidity specifically to
longer TCR:pMHC off-rates (Allard et al., 2017; Gannon et al., 2015;
Hebeisen et al., 2015; Nauerth et al., 2013; Schmid, 2010)). We next
measured the monomeric dissociation constant rates (koff) using dually
labeled pMHC multimers built on NTA-Ni2+-His-tag interactions called
NTAmers (Schmidt et al., 2011, 2013). We found that the off-rate koff
was highly decreased for A2/LLW-8H and -8Q compared to A2/LLL-WT
Fig. 2. Functional properties of the YF5048 clone following stimulation with mutant peptides identified by the CPL. A, Killing capacity (51-chromium release
assay) with titration of the different peptides as indicated. Data are the combination of 3 independent experiments (mean and SEM). B, The EC50 values of the 3
independent 51-chromium release assays shown in A (mean and SEM). C, Intracellular cytokine staining following peptides stimulation for 4 h. Data are the
combination of 3 independent experiments (mean and SEM). IL-2 expression was assessed in only 2 independent experiments. D, Values of the 3 independent
intracellular cytokine staining are expressed as EC50 (mean and SEM). P-values from unpaired t-tests: ns = not significant, *< 0.05, **< 0.01, ***< 0.001.
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(Figs. 3C, S4 and S5). Rather unexpectedly, no significant difference
was observed for the koff of A2/LLW-7I compared to A2/LLW-WT, such
that changes in off-rates could not explain increased sensitivity of the
LLW-7I peptide.
These data show that all three mutant peptides improved the KD
values compared to the WT peptide. In contrast to the A2/LLW-8H and
-8Q peptides, the koff value of the LLW-7I peptide was not significantly
lower compared to the WT peptide.
3.3. In silico modeling shows no particular structural advantage in the 7I
mutation of LLW, while the 8Q and 8H mutations show favorable contacts
with the TCR
In order to address structural determinants of the TCR:pMHC in-
teraction, we solved the atomic structure of the A2/LLW-7I, A2/LLW-
8H and A2/LLW-8Q pMHC complexes (Table S1). We performed in si-
lico modeling based on our crystal structures of the three mutant pMHC
complex and the previously solved structure of the MEL5 TCR (Cole
et al., 2009), which has a TCR α chain that is very close in sequence to
the TCR α chain of YF5048 (Bovay et al., 2017). In these modeled
structures, the LLW-8H and -8Q mutant peptides made favorable con-
tacts with the TCR (Fig. 4A), which would explain the higher TCR
avidity measured by NTAmer. In contrast, the 7I substitution did not
introduce additional favorable contacts with the TCR (Fig. 4B). This is
in line with the lack of a particular advantage in TCR:pMHC koff as
measured by NTAmer for the 7I mutation (Fig. 3), but still did not
explain the increased functional avidity based on immunoassays upon
titration with the 7I peptide (Fig. 2).
Thus, our data shows that a substitution to an isoleucine at P7 does
not change the TCR koff. This was further supported by our in silico
model which shows that the 7I mutant peptide does not make more
favorable contacts with the TCR compared to the WT peptide. The su-
perior T cell function induced by the LLW-7I mutant peptide was
therefore unlikely to be due to increased structural TCR:pMHC inter-
actions.
In contrast, our data suggest that the LLW-8H and -8Q mutant
peptides made favorable contacts with the TCR, supporting the sig-
nificantly longer off-rates and lower KD values compared to the WT
peptide.
3.4. The 7I mutant peptide shows higher entropy loss and rigidity in complex
with HLA-A*02
The enhanced T cell function observed after stimulation with the 7I
mutant peptide could result from the inherent properties of the pMHC
complex. To assess this, we expressed, refolded and purified HLA-
A*0201 in complex with the mutant and WT peptides. To assay the
peptide binding affinity to the MHC molecule, we performed circular
dichroism (CD) temperature melting experiments (Fig. 5A). The A2/
LLW-7I, A2/LLW-8H and A2/LLW-8Q complexes showed a melting
temperature Tm of 66.2, 65.2, 65.3 °C, respectively. Thus, the stability
of the mutant complexes was not significantly different from the A2/
LLW-WT complex (Tm of 66.5 °C, ΔHvH of −488 kJ/mol) (Fig. 5B).
The values of transition enthalpies ΔHvH were also calculated from
the same experiments (Fig. 5B, bottom). The binding of the LLW-7I
peptide to the MHC shows a lower, i.e. more favorable, ΔHvH than the
other peptides, suggesting that the entropy loss upon binding is greater
and that the resultant LLW-7I mutant pMHC complex is more rigid than
the LLW-WT pMHC complex.
In order to investigate pMHC rigidity further, we performed mole-
cular dynamics (MD) simulations of the A2/LLW pMHC complex var-
iants starting from the crystal structures of the A2/LLW-7I, A2/LLW-8H
and A2/LLW-8Q complexes. The Root Mean Square Fluctuations
(RMSF) of the different peptide and MHC residues were calculated. The
latter constitute a measure of the vibration intensity of the residues
around their average position: a residue is more flexible if its RMSF
value is higher. In the A2/LLW-WT complex, the peptide residues Leu1,
Asn4 and Met7, which are facing the solvent in the absence of TCR, are
the most flexible residues, while the peptide residues Leu2, Trp3 and
Val9, which are buried into the MHC pockets, are less flexible (Fig. 6A).
Interestingly, the isoleucine substitution at P7 of the LLW-7I mutant
peptide in the pMHC complex showed a significantly decreased flex-
ibility compared to Met7 in the LLW-WT pMHC complex (Fig. 6A).
As expected, the difference between the RMSF of the other peptide
residues between the LLW-WT and -7I mutant were not significant
(Fig. 6A). Also, the flexibility of Met7 in the LLW-8H and LLW-8Q
mutants was similar to that of the WT peptide.
His8 and Gln8 contain more dihedral angles than the Ala8 residue in
the WT system, and can be expected to display more flexibility when
they face the solvent, in absence of TCR. This is indeed what was ob-
served in the MD simulations for residues His8 and Gln8, in the MD
simulations of the A2/LLW-8H and -8Q complexes, compared to Ala8 of
the WT complex. However, this increase in flexibility compared to Ala8
was limited and not statistically significant (Fig. 6A). The corre-
sponding small entropy penalty upon binding for the mutated systems
was compensated by the additional interactions made between the His8
or Gln8 side chains and TCR, compared to Ala8 in the WT system as
suggested by our in silico model (Fig. 4A and B).
The peptide substitutions could potentially modify the MHC flex-
ibility. To control for this, the RMSF of the MHC residues were calcu-
lated from the same MD simulations (Fig. 6B). No significant difference
could be observed in the flexibility of the MHC residues upon peptide
mutation. Glu154 showed a higher flexibility in the A2/LLW-7I com-
plex compared to the WT pMHC. However, this residue was not in
contact with the mutation site, and the difference in the RMSF was not
statistically significant. The only exception is the higher flexibility of
Fig. 3. TCR affinity of the YF5048 clone towards mutant peptides. A, Representative experiment comparing the geometric mean fluorescent intensities (GMFI)
values of the YF5048 clone stained with the wild-type and mutant pMHC multimer at different concentrations. B, KD values of the 3 independent multimer stainings
at different concentrations were calculated assuming a one-site binding model as implemented in GraphPad. (mean and SEM). C, TCR dissociation rates (koff) of the
NTAmer Cy5 decay normalized to PE background, calculated from the data of the 3 independent experiments (mean and SEM). P-values from unpaired t-tests: ns =
not significant, *< 0.05, **<0.01, ***<0.001.
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Thr73, in the A2/LLW-7I and -8H complexes, which was statistically
significant. This MHC residue is close to residues 7 and 8 of the peptide,
providing a potential explanation for how its flexibility could be im-
pacted by mutations at these positions of the peptide. However, the
absolute values and the differences in the RMSF remained small.
4. Discussion
While several reports have positively correlated functional avidity
specifically to longer TCR:pMHC off-rates (Allard et al., 2017; Gannon
et al., 2015; Hebeisen et al., 2015; Nauerth et al., 2013; Schmid, 2010)),
our data shows that a substitution to an isoleucine at P7 does not
change the TCR:pMHC off-rates. This was further supported by our in
silico model which shows that the 7I mutant and wild type peptides
make similar interactions with the TCR. The superior T cell function
induced by the LLW-7I mutant peptide is therefore not due to an in-
creased interface with the TCR. In contrast, the LLW-8H and -8Q mu-
tant peptides display longer TCR:pMHC off-rates and the in silico
Fig. 4. Molecular modeling of the YF5048 TCR bound to the various mutant peptides in complex with HLA-A2. Ribbons represent TCR β –chain in grey; the
MHC molecule in tan ribbon, and peptides in ball and stick representation. A, WT peptide on left (in grey), 8H peptide on the right (in orange), and 8Q peptide on the
right (in green). C, WT peptide on left (in grey) and 7I peptide on the right (in light blue).
Fig. 5. Stability of the mutant peptides binding to HLA-
A*0201. A) CD melting curves were recorded at 216 nm from
4 °C to circa 70 °C in a 0.1-cm cuvette at cprot∼ 3.5 μM. Dots
represent measured values fitted assuming a two-state trimer-
to-monomer transition (solid lines). B) Apparent melting tem-
peratures Tm (top) and van’t Hoff’s enthalpies of unfolding
ΔHvH (bottom) resulting from the fit are shown as histograms.
Errors bars represent S.D. resulting from the multivariable
curve fitting. Data for LLW-WT and LLW-4A were previously
published (Bovay et al., 2017) and included to allow for a
direct comparison.
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modeling suggests these peptides make more favorable contacts with
the TCR, supporting the significantly higher TCR avidity compared to
the WT peptide.
Position 7 of a nonamer peptide is not usually considered as a pri-
mary MHC anchor residue. We indeed did not find any significant
change in thermal stability for A2/LLW-7I compared to the WT com-
plex. However, supported by experimental ΔHvH values and in silico
molecular dynamics simulations, our results suggest that the LLW-7I
mutant peptide binds the MHC molecule with higher rigidity. It has
been shown that peptide motion, which also impacts MHC motion, af-
fects recognition by the TCR (Ayres et al., 2017). Along these lines, the
larger binding avidity of the A2/LLW-7I complex for the TCR compared
to the A2/LLW-WT complex can be explained by the more limited
flexibility of the isoleucine side chain before binding the TCR (i.e. in
absence of the TCR) which translates into a lower entropy penalty upon
TCR binding (Ayres et al., 2017). The A2/LLW-7I complex seems to be
enthalpically favorable and more rigid than the A2/LLW-WT complex.
This is supporting a better recognition of the interface by the TCR as
less induced fit is required. While our experimental data shows that the
7I mutation does not alter the TCR dissociation rate (koff) measured
using the NTAmer technology, we hypothesize it improves the TCR
association rate (kon) of the TCR-pMHC complex as the dissociation
constant KD (kon/koff) is lower than for the WT pMHC complex. Con-
sequently, this improved KD value could explain the 10-fold higher
antigen sensitivity observed with immunoassays on the YF5048 clone.
The CPL also identified two substitutions at position 8 (LLW-8H and
LLW-8Q) which behave similarly. These two substitutions showed none
(LLW-8Q) or only modest (LLW-8H) enhancement of the antigen sen-
sitivity compared to LLW-WT. However, we found that the TCR dis-
sociation rate (koff measured by NTAmer) and KD value were sig-
nificantly lower compared to A2/LLW-WT. This was further supported
by our in silico modeling suggesting that the TCR makes favorable in-
teractions with the mutated residues. A potential explanation would be
that, although 8H and 8Q substitutions improve the favorable interac-
tion with the TCR, the threshold for maximal T cell responses might
have been reached (Dutoit et al., 2001; Gannon et al., 2015; Speiser
et al., 2008; Tan et al., 2015; Zhong et al., 2013).
In conclusion, our work exemplifies that the superior sensitivity of
an altered peptide (LLW-7I) is not provided by an optimal interaction
with the TCR. Instead, our data suggests that the improved T cell
function could rather result from increased pMHC complex rigidity.
This would facilitate binding to the TCR by limiting the entropy pen-
alty, and consequently increasing the association rate as shown by an
improved KD value.
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